Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM i...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/11/2/22 |
| _version_ | 1827662888492335104 |
|---|---|
| author | Waqqas Tai Ahsan Wahab Diana Franco Zunairah Shah Aqsa Ashraf Qurrat-Ul-Ain Abid Yaqub Nadeem Mohammed Darshan Lal Faiz Anwer |
| author_facet | Waqqas Tai Ahsan Wahab Diana Franco Zunairah Shah Aqsa Ashraf Qurrat-Ul-Ain Abid Yaqub Nadeem Mohammed Darshan Lal Faiz Anwer |
| author_sort | Waqqas Tai |
| collection | DOAJ |
| description | Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with the introduction of newer therapeutics agents, i.e., target-specific monoclonal antibodies. The currently available literature lacks the benefits of newer targeted therapy being developed with an aim to reduce side effects and increase effectiveness, compared to conventional chemotherapy regimens. This article aims to review literature about the current available monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies for the treatment of MM. |
| first_indexed | 2024-03-10T00:35:12Z |
| format | Article |
| id | doaj.art-388a3ebc82c14ed5b880996282134ab1 |
| institution | Directory Open Access Journal |
| issn | 2073-4468 |
| language | English |
| last_indexed | 2024-03-10T00:35:12Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj.art-388a3ebc82c14ed5b880996282134ab12023-11-23T15:18:05ZengMDPI AGAntibodies2073-44682022-03-011122210.3390/antib11020022Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple MyelomaWaqqas Tai0Ahsan Wahab1Diana Franco2Zunairah Shah3Aqsa Ashraf4Qurrat-Ul-Ain Abid5Yaqub Nadeem Mohammed6Darshan Lal7Faiz Anwer8Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY 11201, USADepartment of Internal Medicine, Prattville Baptist Hospital, Prattville, AL 36066, USADepartment of Internal Medicine, Loyola MacNeal Hospital, Berwyn, IL 60402, USADepartment of Internal Medicine, Weiss Memorial Hospital, Chicago, IL 60640, USADepartment of Internal Medicine, Northwell Health, Mather Hospital, Port Jefferson, NY 11777, USADepartment of Internal Medicine, AMITA Health Saint Joseph Hospital, Chicago, IL 60657, USADepartment of Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, MI 48341, USADepartment of Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV 89102, USATaussig Cancer Center, Myeloma Program, Cleveland Clinic, Cleveland, OH 44106, USAMultiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with the introduction of newer therapeutics agents, i.e., target-specific monoclonal antibodies. The currently available literature lacks the benefits of newer targeted therapy being developed with an aim to reduce side effects and increase effectiveness, compared to conventional chemotherapy regimens. This article aims to review literature about the current available monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies for the treatment of MM.https://www.mdpi.com/2073-4468/11/2/22multiple myelomaimmunotherapyantibodytargeted therapyantibody drug conjugatebispecific antibody |
| spellingShingle | Waqqas Tai Ahsan Wahab Diana Franco Zunairah Shah Aqsa Ashraf Qurrat-Ul-Ain Abid Yaqub Nadeem Mohammed Darshan Lal Faiz Anwer Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma Antibodies multiple myeloma immunotherapy antibody targeted therapy antibody drug conjugate bispecific antibody |
| title | Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma |
| title_full | Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma |
| title_fullStr | Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma |
| title_full_unstemmed | Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma |
| title_short | Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma |
| title_sort | emerging role of antibody drug conjugates and bispecific antibodies for the treatment of multiple myeloma |
| topic | multiple myeloma immunotherapy antibody targeted therapy antibody drug conjugate bispecific antibody |
| url | https://www.mdpi.com/2073-4468/11/2/22 |
| work_keys_str_mv | AT waqqastai emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma AT ahsanwahab emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma AT dianafranco emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma AT zunairahshah emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma AT aqsaashraf emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma AT qurratulainabid emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma AT yaqubnadeemmohammed emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma AT darshanlal emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma AT faizanwer emergingroleofantibodydrugconjugatesandbispecificantibodiesforthetreatmentofmultiplemyeloma |